載入...
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility Gene (BRCA)-mutated or homologous recombination-deficient tumor cells can induce “synthetic lethality”, which targets two DNA re...
Na minha lista:
| 發表在: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519338/ https://ncbi.nlm.nih.gov/pubmed/31191001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S200524 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|